Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429399 | 1.00 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRNPSR1CYP19A1 | |
| SCHEMBL12014 | 1.00 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRNPSR1CYP19A1 | |
| SCHEMBL10707153 | 0.92 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10486149 | 0.92 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10486145 | 0.92 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3935881 | 0.88 | — | — | |
| SCHEMBL12855787 | 0.87 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL184319 | 0.87 | — | — | |
| SCHEMBL20664256 | 0.86 | — | — | |
| SCHEMBL20664323 | 0.86 | HCRTR2 (0.33) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212523-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022026823-A1 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2018081294-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | MIDCAP FINANCIAL TRUST | 2018-04-26 | — | — | US | disclosed |
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| WO-2016147659-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-22 | — | — | WO | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2185513-B1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-7649000-B2 | (2'S,2''R)-4-(2'-(2''-amino-3''-(4'''-ethoxyphenyl)propanoylamino)-3'-phenylpropanoyl-amino)piperidine- 1-carboxamidine; inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation | VANTIA LIMITED (GB) | 2010-01-19 | — | — | US | disclosed |
| US-7649000-B2 | (2'S,2''R)-4-(2'-(2''-amino-3''-(4'''-ethoxyphenyl)propanoylamino)-3'-phenylpropanoyl-amino)piperidine- 1-carboxamidine; inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation | VANTIA LIMITED (GB) | 2010-01-19 | — | — | US | disclosed |
| US-20090093501-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| US-20090093501-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2003076458-A2 | SELECTIVE DIPEPTIDE INHIBITORS OF KALLIKREIN | FERRING BV (NL) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | ALDH1A1 1576/4885SMN1; SMN2 3655/4885TSHR 866/4885 |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | ALDH1A1 2666/4885SMN1; SMN2 286/4885TSHR 154/4885 |
| US-20090093501-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | ALDH1A1 662/4885SMN1; SMN2 3148/4885TSHR 549/4885 |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | ALDH1A1 1076/4885SMN1; SMN2 1697/4885TSHR 3008/4885 |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | ALDH1A1 3447/4885SMN1; SMN2 4482/4885TSHR 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.